BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25552705)

  • 1. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.
    Chevallier P; Huguet F; Raffoux E; Etienne A; Leguay T; Isnard F; Robillard N; Guillaume T; Delaunay J; Charbonnier A; Pigneux A; Peterlin P; Bené MC; Wegener WA; Goldenberg DM; Dombret H
    Haematologica; 2015 Apr; 100(4):e128-31. PubMed ID: 25552705
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.
    Chevallier P; Chantepie S; Huguet F; Raffoux E; Thomas X; Leguay T; Marchand T; Isnard F; Charbonnier A; Maury S; Gallego-Hernanz MP; Robillard N; Guillaume T; Peterlin P; Garnier A; Rialland F; Le Houerou C; Goldenberg DM; Wegener WA; Béné MC; Dombret H
    Haematologica; 2017 May; 102(5):e184-e186. PubMed ID: 28154086
    [No Abstract]   [Full Text] [Related]  

  • 3. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.
    Thota S; Advani A
    Eur J Haematol; 2017 May; 98(5):425-434. PubMed ID: 28152223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
    Raetz EA; Cairo MS; Borowitz MJ; Blaney SM; Krailo MD; Leil TA; Reid JM; Goldenberg DM; Wegener WA; Carroll WL; Adamson PC;
    J Clin Oncol; 2008 Aug; 26(22):3756-62. PubMed ID: 18669463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle.
    Chevallier P; Bodet-Milin C; Robillard N; Eugene T; Menard A; Le Houerou C; Guillaume T; Delaunay J; Escoffre-Barbe M; Wegener WA; Goldenberg DM; Kraeber-Bodéré F
    Eur J Haematol; 2013 Dec; 91(6):552-6. PubMed ID: 23927500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.
    Advani AS; McDonough S; Coutre S; Wood B; Radich J; Mims M; O'Donnell M; Elkins S; Becker M; Othus M; Appelbaum FR
    Br J Haematol; 2014 May; 165(4):504-9. PubMed ID: 24579885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.
    Chevallier P; Eugene T; Robillard N; Isnard F; Nicolini F; Escoffre-Barbe M; Huguet F; Hunault M; Marcais A; Gaschet J; Cherel M; Guillaume T; Delaunay J; Peterlin P; Eveillard M; Thomas X; Ifrah N; Lapusan S; Bodet-Milin C; Barbet J; Faivre-Chauvet A; Ferrer L; Bene MC; Le Houerou C; Goldenberg DM; Wegener WA; Kraeber-Bodéré F
    Lancet Haematol; 2015 Mar; 2(3):e108-17. PubMed ID: 26687796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia.
    Bertamini L; Nanni J; Marconi G; Abbenante M; Robustelli V; Bacci F; Matti A; Paolini S; Sartor C; Monaco SL; Fontana MC; De Polo S; Cavo M; Curti A; Martinelli G; Papayannidis C
    BMC Cancer; 2018 Nov; 18(1):1117. PubMed ID: 30442119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
    Wynne J; Wright D; Stock W
    Blood Adv; 2019 Jan; 3(1):96-104. PubMed ID: 30622147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia.
    Papayannidis C; Derenzini E; Iacobucci I; Curti A; Paolini S; Cilloni D; Baccarani M; Martinelli G
    Am J Hematol; 2009 Dec; 84(12):849-50. PubMed ID: 19844989
    [No Abstract]   [Full Text] [Related]  

  • 11. Daratumumab for quick and sustained remission in post-transplant relapsed/refractory acute lymphoblastic leukemia.
    Zhang Y; Xue S; Liu F; Wang J
    Leuk Res; 2020 Apr; 91():106332. PubMed ID: 32126433
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
    Short NJ; Kantarjian H; Jabbour E; Cortes JE; Thomas DA; Rytting ME; Daver N; Alvarado Y; Konopleva M; Kebriaei P; Wierda WG; DiNardo CD; Bivins C; McCue D; Richie MA; Ravandi F
    Br J Haematol; 2018 Aug; 182(3):442-444. PubMed ID: 28616864
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
    Sullivan-Chang L; O'Donnell RT; Tuscano JM
    BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABL deletion without associated BCR-ABL in precursor B-cell acute lymphoblastic leukemia.
    Lo A; Gu G; Liu M; Dev VG
    Leuk Res; 2009 Aug; 33(8):e98-103. PubMed ID: 19282030
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series.
    Chevallier P; Pigneux A; Robillard N; Ayari S; Guillaume T; Delaunay J; Eveillard M; Dumas PY; Lippert E; Mohty M; Leguay T
    Leuk Res; 2012 Mar; 36(3):311-5. PubMed ID: 22172463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of CD22 expression and expansion of a CD22
    Reinert J; Beitzen-Heineke A; Wethmar K; Stelljes M; Fiedler W; Schwartz S
    Ann Hematol; 2021 Nov; 100(11):2727-2732. PubMed ID: 34331563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.
    Kantarjian HM; Stein AS; Bargou RC; Grande Garcia C; Larson RA; Stelljes M; Gökbuget N; Zugmaier G; Benjamin JE; Zhang A; Jia C; Topp MS
    Cancer; 2016 Jul; 122(14):2178-85. PubMed ID: 27143254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
    Dahl J; Marx K; Jabbour E
    Expert Rev Hematol; 2016; 9(4):329-34. PubMed ID: 26783163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inotuzumab ozogamicin (Besponsa)--an antibody-drug conjugate for ALL.
    Med Lett Drugs Ther; 2018 May; 60(1547):e90-e91. PubMed ID: 29913470
    [No Abstract]   [Full Text] [Related]  

  • 20. Trial initiated for liposomal vincristine in relapsed/refractory acute lymphoblastic leukemia.
    Oncology (Williston Park); 2006 Sep; 20(10):1292. PubMed ID: 17024874
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.